Skip to main navigation Skip to search Skip to main content

What's new in eyelid tumors

  • SUNY Downstate Health Sciences University

Research output: Contribution to journalReview articlepeer-review

59 Scopus citations

Abstract

Eyelid malignancies represent between 5% and 10% of all skin cancers. Basal cell carcinoma is the most common, followed by squamous cell carcinoma, sebaceous cell carcinoma, Merkel cell carcinoma, and melanoma. The gold standard treatment for periocular epithelial malignancies is surgical excision. Given the constraints of the anatomy and function of the eyelids, excision with negative margins and reconstruction can be challenging. In cases of significant tissue invasion or metastasis, complete tumor removal may not be possible. This review examines the management of periocular skin cancer from diagnosis and staging, including the role of sentinel lymph node biopsy, to both surgical and nonsurgical treatment. The development of targeted drug therapy against specific genetic mutations in cutaneous malignancies has allowed for the treatment of specific cancer cells with less systemic toxicity than more traditional treatments.

Original languageEnglish
Pages (from-to)143-152
Number of pages10
JournalAsia-Pacific Journal of Ophthalmology
Volume6
Issue number2
DOIs
StatePublished - 2017

Keywords

  • Cancer
  • Eyelid
  • Malignancy

Fingerprint

Dive into the research topics of 'What's new in eyelid tumors'. Together they form a unique fingerprint.

Cite this